Home › Science › PNAS Study Identifies TBC1D9 and TBC1D
SCIENCE
PNAS Study Identifies TBC1D9 and TBC1D9B as ARL8 Effectors
PNAS published research showing TBC1D9 and TBC1D9B act as ARL8 effectors modulating exosome secretion via a RAB11A–exocyst pathway.
By Xentir Media Newsroom · Editorial standards by Jomon · August 07, 2026 · 1 min read
WHAT YOU NEED TO KNOW
PNAS published peer-reviewed findings on TBC1D9 and TBC1D9B on July 23, 2026.
The study identifies TBC1D9 and TBC1D9B as ARL8 effectors.
The effectors modulate exosome secretion through a RAB11A–exocyst pathway.
The research is published under DOI 10.1073/pnas.2527864123.
PNAS published peer-reviewed research on July 23, 2026, establishing key molecular components involved in cellular transport. The study identifies TBC1D9 and TBC1D9B as functional effectors of ARL8.
The findings demonstrate that TBC1D9 and TBC1D9B modulate exosome secretion. This regulatory mechanism functions directly through a RAB11A–exocyst pathway.
PNAS published the paper at 07:00 UTC. The article is indexed under the digital object identifier 10.1073/pnas.2527864123.
Xentir Media NewsroomSource-backed AI and technology coverage, drafted by Xentir's automated editorial system under fixed human-set rules. See our editorial policy and AI usage policy.
Jomon · Founder & EditorFounder and editor of Xentir Media. Sets the editorial rules the newsroom system runs under, and is accountable for its corrections. About Jomon · [email protected]
The Xentir Brief The developments worth knowing — one useful email. Get the Brief →
